Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 15/20 | 0.76 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086538 | 0.90 | HIF1A (0.77) | HIF1ACNR2 | |
| SCHEMBL17578427 | 0.86 | HIF1A (1.00) | HIF1A | |
| SCHEMBL19086523 | 0.82 | HIF1A (0.52) | HIF1AGSK3BKDM4ECNR1CNR2 | |
| SCHEMBL19086529 | 0.82 | HIF1A (0.71) | HIF1A | |
| SCHEMBL29950463 | 0.78 | GSK3B (0.54) | HIF1AGSK3BKDM4EMAPK1HTT | |
| SCHEMBL28849094 | 0.78 | GSK3B (0.54) | HIF1AGSK3BKDM4EMAPK1HTT | |
| SCHEMBL17578541 | 0.77 | HIF1A (1.00) | HIF1A | |
| SCHEMBL19113461 | 0.76 | HIF1A (0.69) | HIF1ACNR1CNR2 | |
| SCHEMBL5334611 | 0.76 | KDM4E (0.59) | HIF1AKDM4EHTT | |
| SCHEMBL23953026 | 0.75 | HIF1A (0.67) | HIF1ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190104-B1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10065928-B2 | Quinolinone compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3190104-A1 | QUINOLINONE COMPOUND AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885GSK3B 1188/4885KDM4E 729/4885 |
| US-10065928-B2 | Quinolinone compound and use thereof | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885GSK3B 1188/4885KDM4E 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.